



Provincial Health Services Authority

Cancer Drug Manual©

Introduction

The main objective of the Cancer Drug Manual© (CDM) is to provide a timely, accurate, and unbiased reference source for health care professionals caring for cancer patients. The manual contains concise, evaluative information on oncology drugs recommended for use by the BC Cancer. Information is presented using a standardized format for consistency and readability.

Documents are written by oncology pharmacists, often with input from clinicians experienced in the use of the particular drug. These documents are then reviewed and approved by a multidisciplinary editorial board of oncology pharmacists, medical oncologists and oncology nurses, to ensure the quality, completeness, and clinical relevance of the information.

The Cancer Drug Manual© is a general drug information resource. For issues of therapeutics, the reader is referred to the BC Cancer Chemotherapy Protocols and the Cancer Management Guidelines, or the most current literature.

Any health professional using the information of the Cancer Drug Manual© to provide treatment for patients will be solely responsible for verifying the doses, providing the prescriptions, and administering the medications described in the manual according to acceptable standards of care. Use of this site and any information on it is at your own risk, and is subject to our [Terms of Use](#).

Referencing the Cancer Drug Manual© (suggested style):

Abiraterone Monograph. Revised 1 August 2017. In: BC Cancer Drug Manual©. Badry, Nadine (editor). BC Cancer. Vancouver, British Columbia. Available at <http://www.bccancer.bc.ca/>. (Accessed 14 February 2019).

Permission Requests

To request permission to use Cancer Drug Manual© material, email your request to BC Cancer Drug Information at druginfo@bccancer.bc.ca.

We are striving for excellence. User feedback is encouraged to help us achieve that goal.

Nadine Badry, BScPharm, ACPR
Editor, Cancer Drug Manual©, BC Cancer